Click a story to read more about the impact of our research. .

Every donation to NBCRI is an act of hope.

  • For the person newly diagnosed with breast cancer, it means access to research that could improve their treatment, reduce side effects or make life during and after cancer healthier and happier.
  • For future patients, it means new knowledge, better care and opportunities that may not otherwise exist.

Over the past two years, NBCRI-funded research nurses, Grainne McDonnell and Claire Hackett, working with Prof Aoife Lowery, Prof Maccon Keane and clinical research colleagues, have helped women across Galway and the West and North-West of Ireland participate in studies that are changing not only how breast cancer is treated, but how people live with and beyond cancer. Here we focus on the impact of three remarkable studies: UCARE, OASIS-4 and eCAN.

Caring for the Heart during Cancer treatment: The UCARE Study

For many women, completing breast cancer treatment is not the end of the journey. Modern treatments have dramatically improved survival, but some can have lasting effects on the heart.

The UCARE study brought together oncology and cardiology specialists to address an important question: how can we better protect the heart health of patients with breast cancer during and after treatment?

One hundred women from across the West and North-West of Ireland joined the study, receiving specialised cardiovascular assessments and follow-up throughout their cancer journey. Those women were not only caring for their own health; they were helping build a new model of survivorship care. Their participation is helping researchers understand how heart problems can be identified earlier and managed more effectively during and after cancer treatment. The knowledge gained will help shape future services so that surviving cancer is not simply about living longer but living well.

For many donors, patients and families, this is the impact they hope to achieve: ensuring that life during and after cancer is healthier, safer and filled with possibility.

Helping Women Stay on Life-Saving Treatment: The OASIS-4 Study

Breast cancer treatment does not end when chemotherapy or surgery is over. Many women spend years taking hormone therapies that reduce the risk of their cancer returning.

These treatments save lives, but they can come with severe menopausal symptoms, including hot flushes, night sweats, changes in mood and disrupted sleep. For some women, the burden of these side effects can become overwhelming.

Through the OASIS-4 clinical trial, local patients helped test a new treatment designed to relieve these symptoms. The study successfully showed that women receiving the new treatment experienced significant improvements in hot flushes, night sweats, sleep quality and overall wellbeing.

To someone who has never experienced them, hot flushes may sound minor. But for a woman trying to recover from cancer, sleep through the night, return to work and regain a sense of normality, they can have a major impact on daily life.

The women who took part in OASIS-4 helped demonstrate that improving quality of life matters just as much as improving survival. Their contribution could help thousands of women around the world remain on life-saving treatment without sacrificing their wellbeing.

Bringing Care Closer to Home: The eCAN Study

For many patients living in rural Ireland, cancer care is about more than medical treatment. It often involves long journeys, time away from family and repeated trips to hospital.

The eCAN project explored whether technology could make supportive cancer care more accessible. This multi-centre trial included patients from 16 countries across Europe including Ireland.

Patients used telemedicine and digital monitoring tools to connect with healthcare professionals remotely, access rehabilitation services and receive psychological support without always needing to travel.

The results were encouraging. Patients reported improvements in quality of life, physical functioning and participation in everyday activities. Those with advanced cancer reported lower levels of psychological distress.

For patients living many miles from specialist centres, this research offers a vision of a future where excellent care can reach people wherever they live. By participating in eCAN, local patients helped show that innovation can make cancer care more accessible, more equitable and more person-centred.

Why your support matters

At first glance, these studies may seem very different.

One focuses on heart health during and after cancer treatment. Another helps women cope with treatment side effects. A third uses technology to bring care closer to home.

But together they tell a much bigger story.

They are about helping people live better with and beyond cancer. They are about reducing worry, easing burdens, improving quality of life and ensuring that patients can access the same support and trials as those in the world’s leading cancer centres.

None of this happens without clinical research nurses. They are the link between patients and research, supporting participants through every step of a study, answering questions, coordinating care and ensuring that every patient’s contribution leads to meaningful discoveries.

When you donate to NBCRI, you are helping a woman sleep through the night while receiving breast cancer treatment. You are helping survivors protect their heart health after cancer. You are helping patients access expert care closer to home, surrounded by their families and communities.

Most importantly, you are helping ensure that every patient diagnosed tomorrow benefits from the courage and generosity of patients who participate in research today.

 

Triple-negative breast cancer (TNBC) is one of the most challenging forms of breast cancer to treat, and patients urgently need better treatment options. Dr David Perea Pérez‘s research is helping to unlock the potential of the body’s own immune system to fight this disease more effectively.

Our immune system contains specialised white blood cells called Natural Killer (NK) cells, which act as the body’s frontline defence against cancer. Think of them as the body’s natural cancer-fighting army, continuously searching for and eliminating dangerous cells. However, in aggressive cancers such as triple-negative breast cancer, these cells can become exhausted and lose their ability to attack the tumour effectively. David’s research aims to understand why this happens and how these cancer-fighting cells can be re-energised.

Working in the Lambe Institute at University of Galway with Prof Michael O’Dwyer, David studies how NK cells interact with breast cancer cells and investigates how they can be strengthened to survive longer and remain active inside tumours. His research is exploring ways to enhance these cancer-fighting cells so they can continue doing what they do best: finding and destroying cancer cells.

The long-term goal is to develop more effective immunotherapies, treatments that empower a patient’s own immune system to fight cancer. While this research is still at the laboratory stage, it is helping to build the knowledge needed to create the next generation of treatments for patients with triple-negative breast cancer.

Importantly, David’s work is part of an international collaboration with researchers at the University of Würzburg in Germany. Together, the teams are combining advanced cancer-recognition technology where NK cells are modified to express a so called “chimeric antigen receptor” or “CAR”. The resulting CAR-NK cells target proteins on the surface of the cancer cells with the aim of creating more powerful and targeted immune cell therapies to fight and eliminate cancer.

Why Your Support Matters

Every breakthrough in cancer treatment begins with research. Thanks to the generosity of NBCRI supporters, researchers like David can explore bold new ideas and develop innovative approaches that could one day improve outcomes for breast cancer patients and their families. Donor funding is helping to advance discoveries that bring us closer to more effective, personalised treatments and, ultimately, better futures for people diagnosed with breast cancer.

This research is already making an impact.

David’s work has been selected for presentation at the international NK2026 conference, where experts from around the world gather to discuss advances in cancer immunotherapy. These achievements demonstrate how donor-funded research in Ireland is contributing to global efforts to improve breast cancer treatment.